BPSZ-BLISS is naturalistic and designed to obtain outcomes data with minimum impact on BPSZ and clinical processees. METHODS: Data are entered, using an Interactive Voice Response System (IVRS), by MDs at baseline and at usual care visits up to 12 +/-2 months; subjects report self-measured BPs, persistence, compliance, and treatment satisfaction at 3, 6, and 12 months. Final cohort characteristics are reported. RESULTS: After 18 months, 10,067 eligible US subjects have been enrolled by 734 IRB approved MDs. Subjects are 48% male, mean aged 56 (SD = 13) years, and 27% newly diagnosed with hypertension. Most are Caucasian (70%), or African-American (22%); only 5% are Hispanic, or other (3%) ethnicity. Median diastolic and systolic BPs qualifying subjects (without diabetes or kidney disease) for study enrollment were 98 mmHg and 154 mmHg respectively. In chronic hypertensives, most common antihypertension medications prior to baseline were angiotensin receptor blockers (ARB) or ARB combination (38%), calcium channel blockers (CCB) or CCB combination (32%), beta blockers (BB) or BB combination (27%), or angiotensin converting enzyme inhibitors (ACE I) or ACE I combination (24%), and diuretics (18%). Automated IVRS validations have maintained data quality (Յ5% error on key variables). Completion of patient follow-up is scheduled for June 2008. CONCLUSION: An innovative design and automated data management and quality control methodologies have been shown to be feasible to collect MD and patient data in a nationwide health education program. Baseline study data are available for comparison with other real-world datasets.
PCV9 TRENDS IN MORTALITY, LENGTH OF STAY AND READMISSIONS AMONG PATIENTS WITH ACUTE STROKE AT THE NATIONAL HEALTHCARE GROUP, SINGAPORE, 2000-2006
Sun Y 1 , Toh MPHS 1 , Heng BH 1 ,Venketasubramanian N 2 , Cheah TSJ 1 1 National Healthcare Group, Singapore, Singapore, 2 National Neuroscience Institute, Singapore, Singapore OBJECTIVE: To describe the trends of intra-hospital mortality, length of stay (LOS) and readmissions of patients with acute stroke at the National Healthcare Group (NHG), Singapore, 2000 Singapore, -2006 . METHODS: All patients aged 21+ years discharged with a primary diagnosis of stroke from the three public hospitals in NHG from January 2000 to December 2006 were studied. Data extracted from computerized datamart included demographic characteristics; co-morbid conditions; and outcomes of interest; i.e. LOS, intra-hospital mortality, and readmissions within one, three, and six months of discharge. Patients were stratified into hemorrhagic stroke (HS), ischemic stroke (IS) and transient ischaemic attack (TIA). Data were analysed by one-way ANOVA, logistic regression and chi-square test using SPSSv15. RESULTS: During the period 2000-2006, there was a total of 22,428 deaths and discharges of patients with acute stroke. Prevalence of hypertension was highest in HS (>60%), with the rate decreasing significantly from 2000-2006 (p = 0.001) . However, the prevalence of dyslipidaemia was highest among in IS, with a significant increase in rate in all during the period in all types of stroke (p < 0.001). Overall, HS was associated with highest intra-hospital mortality rate (95%CI: 22.3%-24.3%) and longest average LOS (95%CI: 17.1-18.7 days). A significant increasing trend in average LOS (p < 0.001) was noted in both HS and IS. Readmissions within the 1-month, 3-month, and 6-month all decreased significantly over the period (p < 0.001). The readmission rates within 1-month for HS and IS were higher than that of TIA, while there were no difference in readmission rates within three (5%) and six (6%) months for all stroke types. CONCLUSION: More studies into the causes of increased LOS should be carried out. Targeted primary interventions are needed to address the high rates of hypertension among those with IS and the increasing trend in dyslipidaemia among all types of stroke. >10xULN), were estimated by meta-analysis (random effects) and presented in benefit risk planes. RESULTS: Analysis of 25 studies (~24,000 pts) demonstrated rosuvastatin to be significantly more efficacious than atorvastatin, for LDL-c reduction, at 1:1 and 1:2 dosage ratios. There were no significant differences between rosuvastatin and atorvastatin, at any dose ratio, for i) withdrawals due to adverse events, ii) myalgia, iii) serious adverse events, iv) death, v) ALT > 3x upper limit of normal (ULN), and vi) creatine kinase (CK) >10xULN. CONCLUSION: At 1:1 and 1:2 dose ratios, significant additional reductions in LDL-c are obtained by rosuvastatin at a comparable risk of the adverse events presented. To extend beyond the current approach of predicting warfarin benefit and harm independently in new atrial fibrillation (AF) patients by refining methods to identify predictors of the four combined benefit/harm outcome groups-i) no stroke/no bleed; ii) no stroke/bleed; iii) stroke/bleed; iv) no stroke/no bleed. METHODS: We analyzed patient-level data from the Atrial Fibrillation Investigators RCT database (n = 9155) and an observational database of AF patients managed by Kaiser Permanente Colorado (n = 5475). We classified patients based on the four benefit/harm outcome groups and applied decision tree modeling (CART) and polytomous logistic regression (PLR) to identify patient factors predicting each outcome group. Statistical significance was set at alpha = 0.05. RESULTS: CART and PLR consistently identified age and warfarin use as predictors for all outcome groups. Both techniques identified predictors of stroke/no bleed and no stroke/bleed not previously included in AF stroke and bleed risk-assessment tools that predict these outcomes independently (e.g., CHADS2 and HEMORR2HAGES). Methodology strengths and limitations were evident. CART provides a visual algorithm approach to risk. However, there is a lack of quantitative measurement (e.g., odds ratios [OR], confidence intervals) for predictors. While PLR results were thorough and predictor parameter estimates could be converted to ORs to indicate strength of association, the result of PLR is number-intensive. To calculate a patient's probability for each of the four outcome groups, the patient's data must be inputted into three separate equations. While both techniques can be used to calculate an individual patient's probability for each outcome group, PLR likely has more scope for application in a clinical setting. Once refined, a clinical prediction rule could be created based on identified predictors and their ORs.
PCV12 METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM

CONCLUSION:
While methods under study need further refinement, these individual patient data analyses provide a useful step forward in the movement towards evidence-based individualization of drug therapy. Little is known about the frequency of recurrent angina following percutaneous and surgical procedures, the characteristics which put a patient at risk for recurrent angina and the timing of angina recurrence. METHODS: Patients enrolled in a large national managed care plan with a claim for a CABG, PCI or stent from January 1, 2003 to Decemeber 31, 2004 were selected if they were 35 or older, and enrolled one year prior and one year following their procedure. Patients were followed for one year after their index procedure for medication use, angina diagnosis by ICD-9 code and additional revascularization procedures. RESULTS: Following selection criteria 18,240 patients were eligible for analysis. The average age was 59 years, with 25% age 65 years and older. Most patients were male (78%). Of the 18,240 patients, 46% (8420) experienced angina (identified by angina diagnosis and/or two or more nitrate prescriptions) within a year following their index procedure. Of those patients experiencing angina, approximately a third (30%/2904) had another revascularization procedure following the angina diagnosis. The average time from initial procedure to second procedure, after angina diagnosis, was 73 days, although there is a wide range among patients (SD = 103 days). Risk factors for having angina following a revascularization procedure were younger age, female gender and having a PCI without a stent. CONCLUSION: Angina reoccurs in a considerable percentage of patients in the year following a percutaneous or surgical coronary procedure. A third of patients experiencing angina have a second procedure after experiencing recurrent angina. 
PCV14 EVALUATION OF RESISTANT HYPERTENSION IN A USUAL-CARE SETTING
